What is the recommended afatinib dosage and dose adjustments for adults, including considerations for Asian ethnicity, body weight <45 kg, hepatic impairment, and strong CYP3A4 inducers?

Afatinib Dosage Recommendations

The standard starting dose of afatinib is 40 mg once daily taken on an empty stomach (at least 1 hour before or 3 hours after food), with dose reductions to 30 mg or 20 mg based on tolerability. 1

Standard Dosing

• Starting dose: 40 mg once daily
• Administration: Take at least 1 hour before or 3 hours after food (food decreases absorption by 50% for Cmax and 39% for AUC) 1
• Available strengths: 40 mg, 30 mg, and 20 mg tablets 1

Dose Adjustments for Specific Populations

Severe Renal Impairment

Reduce starting dose to 30 mg once daily in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²). 1

• Patients with severe renal impairment have 50% higher AUC and 22% higher Cmax compared to those with normal renal function 1
• No dose adjustment needed for mild-to-moderate renal impairment (eGFR 30-89 mL/min/1.73 m²) 1
• Not studied in patients with eGFR <15 mL/min/1.73 m² or on dialysis 1

Hepatic Impairment

No starting dose adjustment is required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. 1

• For severe hepatic impairment (Child-Pugh C): Not studied, but closely monitor and adjust dose if not tolerated 1

Body Weight <45 kg and Asian Ethnicity

While the FDA label does not specify dose reductions for low body weight or Asian ethnicity, real-world evidence suggests these patients may benefit from lower starting doses. 2

• Real-world data show dose reductions were more common in female, East Asian, and low body-weight patients 2
• Studies in Asian populations demonstrate that 30 mg starting doses achieve comparable efficacy with better tolerability 3, 4
• In a Malaysian real-world study, 60.9% of patients started on doses <40 mg, with higher objective response rates (72.3% vs 54.0%, p=0.032) compared to the 40 mg dose 3

Drug Interactions

Strong P-glycoprotein (P-gp) Inhibitors

Avoid concomitant use with strong P-gp inhibitors when possible. 1

• Ritonavir (P-gp inhibitor) increases afatinib Cmax by 38.5% 5
• If co-administration is unavoidable, separate dosing by 6 hours or more (give P-gp inhibitor 6 hours after afatinib) 1

Strong P-gp Inducers (including CYP3A4 inducers)

Avoid concomitant use with strong P-gp inducers. 1

• Rifampicin decreases afatinib exposure by 34.3% 5
• If unavoidable, consider increasing afatinib dose by 10 mg increments as tolerated, up to 50 mg daily 1

Tolerability-Guided Dose Modifications

Dose reductions for adverse events are common and do not compromise efficacy. 2

Management Algorithm:

1. For Grade 2 adverse events (diarrhea, rash, stomatitis) lasting >7 days or intolerable:

   • Hold afatinib until Grade ≤1
   • Resume at 10 mg lower dose 1

2. For Grade 3+ adverse events:

   • Hold afatinib until Grade ≤1
   • Resume at 10 mg lower dose 1
   • If Grade 3+ recurs at 20 mg, permanently discontinue 1

3. Real-world dosing patterns:

   • 67.1% of patients starting at 40 mg required dose reduction, with 86.5% occurring in first 6 months 2
   • Median time-to-treatment failure (18.7 months) and time-to-progression (20.8 months) were not impacted by dose modifications 2

Clinical Considerations

For Asian patients, elderly patients (≥75 years), or those with body weight <45 kg, consider starting at 30 mg daily to minimize toxicity while maintaining efficacy. 3, 4, 6

• A study of 103 patients ≥75 years showed 89.3% required dose modification, with significantly more reductions in the 40 mg group (93.1%) versus 30 mg group (68.8%, p=0.004) 6
• The 30 mg dose in Asian patients with common EGFR mutations achieved median PFS of 13.97 months with better tolerability 4
• Lower starting doses (≤30 mg) in real-world Malaysian cohort showed superior objective response rates without compromising survival outcomes 3

Common Pitfalls to Avoid:

• Do not take with food - significantly reduces absorption 1
• Do not use in combination with strong CYP3A4/P-gp inhibitors without dose separation 1
• Do not delay dose reduction for persistent Grade 2 toxicities - early intervention maintains treatment adherence 2